Ventracor chalks up first revenues

By Ruth Beran
Tuesday, 20 September, 2005

Ventracor (ASX:VCR) has received its first revenues, in the form of a cheque from the University of Maryland Medical Centre as payment for a VentrAssist left ventricular assist device (LVAD) recently implanted in a patient as part of its US clinical trial.

The company previously indicated it would reach the milestone before the end of 2005.

Related News

Lipid science receives new Australia-led online hub

The Lipid Network launched this month to build links between researchers, clinicians and industry...

Proposed Australian trial eyes up blood testing for Alzheimer's

Utilising networks of GPs across three states, a large-scale study intends on combining digital...

Applications open for $300K pandemic therapeutics fellowships

Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...

Content from other channels on our network

Victoria announces "massive" upgrade to one of its busiest hospitals

NSW IRC decision prompts "mixed emotions" from nurses and midwives

Surgical robot expands its scope of procedures

Neuroscientists propose clinical definition for brain fog in menopause

National Pain Alliance launched to advocate for chronic pain

Six on the shelf: on-the-go protein, ready-to-cook veggies and more

What can food manufacturers learn from viral food trends?

Lion 'flicks the switch' to electric at Speight's Brewery

NZ Winegrowers calls for a White Wine Emoji

Nutrition claims compliance, fresh produce guide updated

Community food network closes its soft plastics recycling loop

Real-time monitoring reduces risk at pumping station

Victorian oil refinery fire may impact fuel supply

Leafy greens identified as potential metal mining tools

Smart monitoring helps tram network cut water use by 70%

All content Copyright © 2026 Westwick-Farrow Pty Ltd